Covid-19 and Vitamin D in Nursing-home (COVIT-EHPAD)
COvid-19 et VITamine d en EHPAD
First epidemiological data about COVID-19 pandemic confirm that older adults are likely to experience severe and lethal forms of SARS-CoV-2 infection, in particular frail elderly living in nursing-homes. Vitamin D could be a biological determinant of COVID-19, as indicated by genomic-guided tracing of SARS-CoV-2 targets in human cells. Epidemiological observational data are necessary for better understanding the links between vitamin D supplementation and COVID-19 outcomes, in particular in nursing-homes (in which the risk of hypovitaminosis D is very high).
The investigators had the opportunity to use information collected in a French middle-sized nursing-home affected by COVID-19 in March-April 2020, to determine whether recent vitamin D3 supplementation was associated with the prognosis of COVID-19 in residents infected with SARS-CoV-2. As recommended in French nursing-homes, all residents are systematically and regularly supplemented with bolus vitamin D3 (every single, 2 or 3 months, depending on residents).
The main objective of this study is to determine whether bolus vitamin D3 supplementation taken during or in the month before COVID-19 was effective in improving survival among frail elderly nursing-home residents infected with COVID-19 compared to those having received supplementation longer ago.
The secondary objective is to determine whether bolus vitamin D3 supplementation taken during or in the month before COVID-19 was effective in limiting the clinical severity of the infection according to the World Health Organization's Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 compared to those having received supplementation longer ago.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Angers, Frankrike, 49933 cedex 9
- Angers University hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Living in the nursing-home of Saint Laurent-de-Chamousset, France, during the COVID-19 epidemic (March-April 2020)
- Being suspected or diagnosed with COVID-19 (RT-PCR, chest CT scan)
Exclusion Criteria:
- Opposition of the resident and/or relatives to the use of anonymized clinical-biological data
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19
Tidsramme: From March 2020 to 15 May 2020
|
From March 2020 to 15 May 2020
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical severity score of COVID19 in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19
Tidsramme: From March 2020 to 15 May 2020
|
Clinical severity score of COVID19 is assessed with Ordinal Scale for Clinical Improvement (OSCI).
OSCI ranges from 0 to 8, higher score meaning poorer outcome.
|
From March 2020 to 15 May 2020
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Cédric ANNWEILER, MD, PhD, University Hospital, Angers
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2020/67
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronavirus
-
VA Office of Research and DevelopmentFullførtSARS Coronavirus 2 RT-PCR TestingForente stater
-
National Institute of Allergy and Infectious Diseases...Naval Medical Research Center; SAb Biotherapeutics, Inc.FullførtMidtøsten respiratorisk syndrom CoronavirusForente stater
-
St. Martin De Porress HospitalRekrutteringCOVID-19 (Coronavirus Disease 2019)Taiwan
-
Bursa Yüksek İhtisas Education and Research HospitalUkjentCoronavirus som årsak til sykdommer klassifisert andre stederTyrkia
-
King Abdullah International Medical Research CenterFullførtMidtøsten respiratorisk syndrom Coronavirus (MERS-CoV)Saudi-Arabia
-
King Abdullah International Medical Research CenterUniversity of OxfordFullførtMidtøsten respiratorisk syndrom CoronavirusSaudi-Arabia
-
Institut National de la Santé Et de la Recherche...FullførtKoronavirusFrankrike, Fransk Guyana
-
PfizerRekrutteringSykdommer i luftveiene | Covid-19 | Lungebetennelse | Lungesykdommer | Koronavirusepidemi 2019 | Coronavirus Disease 2019 (COVID-19) | Covid-19-infeksjon | Infeksjoner i øvre luftveier | Luftveisinfeksjon | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2-infeksjonBelgia
-
Inovio PharmaceuticalsCoalition for Epidemic Preparedness InnovationsFullførtMidtøsten respiratorisk syndrom Coronavirus (MERS-CoV)Libanon, Jordan, Kenya
-
University Hospital, Basel, SwitzerlandsciCORE University of Basel; Leonhard Med IT ETH Zurich; Swiss Institute...FullførtSARS Coronavirus (SARS-CoV-2) infeksjonSveits